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Renal carcinoma appears in both a hereditary and a Mutations in each of the three exons have been found
and include nonsense mutations, substitutions, deletions,sporadic form. Most sporadic renal carcinomas (85%)
and nucleotide insertions. Neither VHL gene LOH orare of the clear cell histological type; papillary renal
VHL mutation has been found in nonclear cell (papil-carcinoma makes up 5 to 10%, with rare histological
lary) renal carcinoma. The characterization of the VHLtypes such as chromophobe and collecting duct renal
suppressor gene product is underway in a number ofcarcinomas making up the remainder. Von Hippel Lin-
different laboratories. Elongin (SIII), the cellular tran-dau (VHL) tumor is the most well-characterized form of
scription factor, has been identified as at least one func-hereditary renal carcinoma. VHL is a hereditary cancer
tional target of the VHL protein. The VHL protein hassyndrome in which affected individuals are at risk to
also been shown to bind specifically and tightly to thedevelop tumors in a number of organs, including the
Elongin C and B subunits and to inhibit Elongin (Slll)kidneys, pancreas, adrenal gland, inner ear, eyes, spine,
transcriptional activity in vitro. A potential locus in theand cerebellum. VHL families may be categorized as
59 end of exon 3 of the VHL gene for VHL Elongin B/CVHL type II (with pheochromocytoma) or VHL type I
binding has been identified. The VHL protein has been(without pheochromocytoma). The manifestations of
found both in the cytosol and nucleus of transiently trans-germline VHL gene mutation in affected individuals are
fected cells. There is a cell density-dependent transportremarkably angiogenic. The central nervous system hem-
of VHL out and/or into the nucleus. A striking featureangioblastomas are extremely hypervascular and have
in the clinical manifestations of VHL disease is angiogen-been shown to produce high levels of vascular endothe-
esis. A high degree of neoangiogenesis also characterizeslial growth factor (VEGF). The retinal angiomas are also
the clinical manifestation of clear cell renal carcinoma.extremely hypervascular, as are the renal cell carcino-
Both cerebellar hemangioblastoma and clear cell renalmas, pheochromocytomas, pancreatic tumors, and the
carcinoma have been shown to have a marked elevationepididymal cystadenomas.
in the expression of VEGF. The reintroduction of theThe VHL gene, which has the characteristics of a tu-
wild-type copy of the VHL gene can reverse the increasedmor suppressor gene, is on chromosome 3, has three
expression of VEGF in renal carcinoma cells. This rever-exons, and encodes a gene of 213 proteins. In tumors
sal can be blocked by either low serum or anoxic condi-from patients with VHL, both copies of the VHL gene
tions.are inactivated; there is generally mutation of the inher-
Hereditary papillary renal cell carcinoma (HPRC) is aited allele and loss of the somatic allele. Genotype/pheno-
hereditary cancer syndrome in which affected individualstype correlations have been made with a germline mutation
are at risk to develop, among other manifestations,of the VHL gene mutation and manifestation observed in
multifocal, bilateral papillary renal cell carcinoma. Thispatients affected with VHL. In the VHL type II families,
syndrome has an autosomal dominant inheritance pat-where there is pheochromocytoma, missense mutations
tern and is distinct from other hereditary renal carcino-of the VHL gene are most often found. A “hot spot”
mas. The disease is characterized by a germline mutationfor VHL type II has been identified in the 59 end of exon 3
of the c-Met protooncogene. The c-Met gene encodesof the VHL gene.
the receptor for hepatocyte growth factor.The clinical manifestations of clear cell renal carci-
noma are characterized by marked angiogenesis. Clear
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Bcl-2 and related proteins have been shown to play nized in a compact, helical bundle, composed of two
central hydrophobic a helices surrounded by amphi-an important role in regulating the susceptibility of cells
of undergoing apoptosis in response to a wide variety of pathic helices. This core structure bears striking similar-
ity to the pore-forming domain found in a number ofstimuli. Although some members of the Bcl-2 family,
including Bcl-2 and Bcl-xL, functionally appear to pre- bacterial toxins. These data suggest the possibility that
Bcl-2 and related proteins maintain the homeostasis ofvent programmed cell death, other family members, in-
cluding Bax and Bak, appear to potentiate apoptosis. key intracellular organelles by regulating membrane per-
meability. The biochemical and evolutionary implica-Although various genetic experiments have confirmed
the central importance of Bcl-2–related proteins in regu- tions of these observations will be discussed.
lating cell survival, the exact biochemical functions per-
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